Management of a patient with heart failure by sacubitril/valsartan: improvement of functional capacity.

We report a case of a 48 year old male with HF with reduced ejection fraction (HFrEF) due to hypertensive cardiomyopathy (New York Heart Association [NYHA] class III). Therapy with sacubitril/valsartan was initiated after some years of other treatments, which did not lead to any positive outcome in HF, quality of life and clinical functions. After only 1 month of sacubitril/valsartan therapy, the patient reported a significant improvement in quality of life, and in 6 months his NYHA class switched from III to I. PMID: 30864899 [PubMed - in process]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research